Microbot Medical Inc.
MBOT Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$0.97
KIRA · Stoqly’s AI analyst, in plain words
- Microbot Medical Inc. lost $13.1M in fiscal 2025.
- Free cash flow was −$13.1M in fiscal 2025, — of revenue.
Market cap
$65.4M
P/E
—
Revenue
—
Net income
−$13.1M
Free cash flow
−$13.1M
Operating margin
—
Microbot Medical Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$13.1M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Microbot Medical Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Microbot Medical Inc.
- CIK
- 0000883975
Microbot Medical Inc. · MBOT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$11.3M | −$13.2M | −$10.7M | −$11.4M | −$13.1M |
| Diluted EPS | −$1.59 | −$1.81 | −$1.05 | −$0.73 | −$0.29 |
| Cash | |||||
| Cash from operations | −$9.4M | −$11.5M | −$8.5M | −$8.8M | −$13.0M |
| Capital expenditure | $0.1M | $0.1M | $0.0M | $0.0M | $0.1M |
| Free cash flow | −$9.4M | −$11.6M | −$8.6M | −$8.9M | −$13.1M |
| Share count change | −0.1% | 2.1% | 40.5% | 53.4% | 192.7% |
| Debt and strength | |||||
| Cash and short-term investments | $15.5M | $8.2M | $6.4M | $5.5M | $78.6M |
| Shareholders' equity | $14.4M | $7.3M | $4.5M | $3.5M | $77.6M |
| Current ratio | 8.0x | 4.3x | 2.1x | 2.4x | 23.3x |
| Returns and quality | |||||
| Return on equity | −58.5% | −121.5% | −182.2% | −285.0% | −32.4% |
| Return on tangible equity | −78.7% | −180.7% | −238.6% | −324.2% | −16.9% |
| Altman Z'' | −3.6 | −24.8 | −34.6 | −57.0 | 21.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Microbot Medical Inc. · MBOT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.97 a share, the company is worth $65.4M.
Source: SEC EDGAR XBRL filings (CIK 0000883975). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.